You do not have permission to edit this page, for the following reasons:

This IP address has been blocked from editing Wikipedia.
This does not affect your ability to read Wikipedia pages.
Most people who see this message have done nothing wrong. Some kinds of blocks restrict editing from specific service providers or telecom companies in response to recent abuse or vandalism, and can sometimes affect other users who are unrelated to that abuse. Review the information below for assistance if you do not believe that you have done anything wrong.

The IP address or range 44.222.0.0/16 has been blocked (disabled) by ‪Blablubbs‬ for the following reason(s):

The IP address that you are currently using has been blocked because it is believed to be a web host provider or colocation provider. To prevent abuse, web hosts and colocation providers may be blocked from editing Wikipedia.
You will not be able to edit Wikipedia using a web host or colocation provider because it hides your IP address, much like a proxy or VPN.
We recommend that you attempt to use another connection to edit. For example, if you use a proxy or VPN to connect to the internet, turn it off when editing Wikipedia. If you edit using a mobile connection, try using a Wi-Fi connection, and vice versa. If you are using a corporate internet connection, switch to a different Wi-Fi network. If you have a Wikipedia account, please log in.
If you do not have any other way to edit Wikipedia, you will need to request an IP block exemption.

How to appeal if you are confident that your connection does not use a colocation provider's IP address:
If you are confident that you are not using a web host, you may appeal this block by adding the following text on your talk page: ((unblock|reason=Caught by a colocation web host block but this host or IP is not a web host. My IP address is _______. Place any further information here. ~~~~)). You must fill in the blank with your IP address for this block to be investigated. Your IP address can be determined here. Alternatively, if you wish to keep your IP address private you can use the unblock ticket request system. There are several reasons you might be editing using the IP address of a web host or colocation provider (such as if you are using VPN software or a business network); please use this method of appeal only if you think your IP address is in fact not a web host or colocation provider.

Administrators: The IP block exemption user right should only be applied to allow users to edit using web host in exceptional circumstances, and requests should usually be directed to the functionaries team via email. If you intend to give the IPBE user right, a CheckUser needs to take a look at the account. This can be requested most easily at SPI Quick Checkuser Requests. Unblocking an IP or IP range with this template is highly discouraged without at least contacting the blocking administrator.

This block will expire on 10:53, 20 August 2024.

Even when blocked, you will usually still be able to edit your user talk page, as well as email administrators and other editors.

For information on how to proceed, please read the FAQ for blocked users and the guideline on block appeals. The guide to appealing blocks may also be helpful.

Other useful links: Blocking policy · Help:I have been blocked
Your IP address is in a range that has been blocked on all Wikimedia Foundation wikis. The block was made by ‪AntiCompositeNumber‬. The reason given is Open proxy/Webhost: Visit the FAQ if you are affected .
- Start of block: 13:57, 18 August 2022
- Expiry of block: 13:57, 18 September 2024
Your current IP address is 44.222.150.245. The blocked range is 44.222.0.0/16. Please include all above details in any queries you make. If you believe you were blocked by mistake, you can find additional information and instructions in the No open proxies global policy. Otherwise, to discuss the block please post a request for review on Meta-Wiki. You could also send an email to the stewards VRT queue at stewards@wikimedia.org including all above details.

You can view and copy the source of this page:

((Short description|Antiplatelet drug))
((multiple issues|
((refimprove|date=November 2014))
((technical|date=September 2021))
))
((Drugbox
| verifiedrevid = 470610777
| image = Tirofiban.svg
| width = 290
| alt = 
| image2 = Tirofiban ball-and-stick.png
| alt2 = 

<!--Clinical data-->
| tradename = Aggrastat
| Drugs.com = ((drugs.com|monograph|tirofiban))
| MedlinePlus = a601210
| DailyMedID = Tirofiban
| pregnancy_AU = B1
| pregnancy_category = 
| routes_of_administration = [[Intravenous therapy|intravenous]]
| ATC_prefix = B01
| ATC_suffix = AC17
| ATC_supplemental = 

| legal_US = Rx-only
| legal_US_comment = <ref name="Aggrastat FDA label">((cite web | title=Aggrastat- tirofiban injection, solution | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe0ced75-ccbf-4d2e-bd0d-b57e60ab913f | access-date=19 June 2021))</ref>
| legal_status = Rx-only

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 65%
| metabolism =  
| elimination_half-life = 2 hours

<!--Identifiers-->
| IUPHAR_ligand = 6586
| CAS_number_Ref = ((cascite|correct|??))
| CAS_number = 144494-65-5
| PubChem = 60947
| DrugBank_Ref = ((drugbankcite|correct|drugbank))
| DrugBank = DB00775
| ChemSpiderID_Ref = ((chemspidercite|correct|chemspider))
| ChemSpiderID = 54912
| UNII_Ref = ((fdacite|correct|FDA))
| UNII = GGX234SI5H
| KEGG_Ref = ((keggcite|correct|kegg))
| KEGG = D08607
| ChEBI_Ref = ((ebicite|correct|EBI))
| ChEBI = 9605
| ChEMBL_Ref = ((ebicite|correct|EBI))
| ChEMBL = 916

<!--Chemical data-->
| C=22 | H=36 | N=2 | O=5 | S=1
| smiles = O=S(=O)(N[C@H](C(=O)O)Cc2ccc(OCCCCC1CCNCC1)cc2)CCCC
| StdInChI_Ref = ((stdinchicite|correct|chemspider))
| StdInChI = 1S/C22H36N2O5S/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26)/t21-/m0/s1
| StdInChIKey_Ref = ((stdinchicite|correct|chemspider))
| StdInChIKey = COKMIXFXJJXBQG-NRFANRHFSA-N
))

'''Tirofiban''', sold under the brand name '''Aggrastat''', is an [[antiplatelet]] [[medication]]. It belongs to a class of antiplatelets named [[glycoprotein IIb/IIIa inhibitors]]. Tirofiban is a small molecule inhibitor of the protein-protein interaction between fibrinogen and the platelet integrin receptor GP IIb/IIIa and is the first drug candidate whose origins can be traced to a [[pharmacophore]]-based [[virtual screening]] [[lead compound|lead]].<ref name="HartmanGD">((cite journal | vauthors = Hartman GD, Egbertson MS, Halczenko W, Laswell WL, Duggan ME, Smith RL, Naylor AM, Manno PD, Lynch RJ, Zhang G | display-authors = 6 | title = Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors | journal = Journal of Medicinal Chemistry | volume = 35 | issue = 24 | pages = 4640–2 | date = November 1992 | pmid = 1469694 | doi = 10.1021/jm00102a020 | publisher = [[American Chemical Society]] ))</ref><ref name="VanDriesJ">((cite journal | vauthors = Van Drie JH | title = Computer-aided drug design: the next 20 years | journal = Journal of Computer-Aided Molecular Design | volume = 21 | issue = 10–11 | pages = 591–601 | year = 2007 | pmid = 17989929 | doi = 10.1007/s10822-007-9142-y | publisher = Springer | bibcode = 2007JCAMD..21..591V | s2cid = 3060340 ))</ref>

It is available as a [[generic medication]].<ref>((cite web | title=First Generic Drug Approvals 2023 | website=U.S. [[Food and Drug Administration]] (FDA) | date=30 May 2023 | url=https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/first-generic-drug-approvals | archive-url=https://web.archive.org/web/20230630003621/https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/first-generic-drug-approvals | archive-date=30 June 2023 | url-status=live | access-date=30 June 2023))</ref>

== Medical uses ==
Tirofiban is [[Indication (medicine)|indicated]] to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in people with non-ST elevation acute coronary syndrome.<ref name="Aggrastat FDA label" />

==Contraindications and precautions==
((unreferenced section|date=June 2021))
Tirofiban is contraindicated in patients with:
* Known hypersensitivity to any component of tirofiban. 
* History of thrombocytopenia with prior exposure to tirofiban. 
* Active internal bleeding, or history of bleeding diathesis, major surgical procedure or severe physical trauma within the previous month.

==Adverse reactions==
((unreferenced section|date=June 2021))
Bleeding is the most commonly reported adverse reaction.

===Use in pregnancy===
((unreferenced section|date=June 2021))
Tirofiban has been demonstrated to cross the [[placenta]] in pregnant [[rat]]s and [[rabbit]]s. Although the doses employed in these studies were a multiple of those used in human beings. no adverse effects on the offspring in both animals have been seen. However, there are no adequate and well controlled studies in pregnant women. Therefore, tirofiban should be used during pregnancy only if clearly indicated.

Nursing mothers: It is not known whether tirofiban is excreted in [[breast milk|human milk]]. However, significant levels of tirofiban are excreted in rat milk. Therefore, nursing should be discontinued during the period of drug administration and the milk discarded. Nursing may resume 24 hours after cessation of treatment with tirofiban.

===Pediatric use===
((unreferenced section|date=June 2021))
Safety and effectiveness in children have not been established.

===Other precautions and laboratory exams===
((unreferenced section|date=June 2021))
The [[partial thromboplastin time|activated partial thromboplastin time]] is the most reliable coagulation parameter and should be obtained regularly during treatment, particular if a bleeding episode occurs that may be associated with tirofiban therapy. Other important hematological parameters are [[platelet count]], [[clotting time]], [[hematocrit]] and [[hemoglobin]]. Proper technique regarding artery site access for sheath placement and removal of sheath should be followed. Arterial sheaths should be removed when the patient's activated clotting time is < 180 seconds or 2 to 6 hours following withdrawal of heparin.

==Side effects==
((unreferenced section|date=June 2021))
The following [[adverse drug reaction|side effect]]s were noted under treatment with tirofiban and heparin (and aspirin, if tolerated). Other drugs were used as necessary.

The major adverse effect is bleeding on local sites of clinical intervention and systemically (regarding parts of the body or the whole body system). Major bleeding has occurred in 1.4% of patients and minor bleeding in 10.5%. [[Blood transfusion|Transfusion]]s were required to terminate bleeding and to improve bleeding-related [[anemia]] in 4.0% of all patients. Geriatric patients have experienced more bleeding episodes than younger, women more than men.

Thrombocytopenia was more often seen in the tirofiban + heparin group (1.5%) than in the heparin control group (0.8%). This adverse effect was usually readily reversible within days.

Positive fecal and urine hemoglobin tests have also been reported.

[[Postmarketing surveillance|Post-marketing event]]s have been the occurrence of intracranial bleeding, retroperitoneal bleeding, [[pulmonary hemorrhage]] and spinal-epidural hematoma. Fatal bleeding have been reported rarely.

Sometimes, thrombocytopenia was associated with [[chills]], low-grade [[fever]] or bleeding complications (see above).

Cases of hypersensitivity including [[anaphylaxis]] have occurred.

== Interactions ==
((unreferenced section|date=June 2021))
The concomitant application of warfarin or other oral anticoagulants may increase the risk of serious bleeding events. The decision whether maintenance therapy with these drugs should be discontinued during tirofiban treatment has to be made by the responsible clinician.

==Pharmacology==
((unreferenced section|date=June 2021))
Tirofiban has a rapid onset and short duration of action after proper IV administration. Coagulation parameters turn to normal 4 to 8 hours after the drug is withdrawn.

==Chemistry==
Tirofiban is a synthetic, non-peptide inhibitor of the interaction of fibrinogen with the integrin glycoprotein IIb/IIIa on human [[platelet]]s. The Merck chemistry team of George Hartman, Melissa Egbertson and Wasyl Halczenko developed tirofiban from a lead compound discovered in focused screening of small molecule replacements of the key arginine-glycine-aspartic acid (Arg-Gly-Asp) subunit of fibrinogen.  Computation of the distance between the charged Arg and Asp sites in fibrinogen provided guidance leading to directed screening success.  Tirofiban constitutes an [[antithrombotic]], specifically an inhibitor of platelet aggregation.

Tirofiban is a modified version of a molecule found in the venom of the saw-scaled viper ''[[Echis carinatus]]''.<ref name="edinburgh">((cite web|url=http://www.portfolio.mvm.ed.ac.uk/studentwebs/session2/group13/vipers.html|title=Saw-Scaled Vipers|publisher=[[University of Edinburgh]]|access-date=2008-06-23|url-status=dead|archive-url=https://web.archive.org/web/20020309201828/http://www.portfolio.mvm.ed.ac.uk/studentwebs/session2/group13/vipers.html|archive-date=2002-03-09))</ref><ref name="pmid31137917">((cite journal | vauthors = Lazarovici P, Marcinkiewicz C, Lelkes PI| title = From snake venom's disintegrins and C-type lectins to anti-platelet drugs| journal = Toxins | volume = 11 | issue = 5 | pages = Article 303 | date = May 2019| pmid = 31137917 | pmc = 6563238 | doi = 10.3390/toxins11050303| doi-access = free))</ref>

==History==
((unreferenced section|date=June 2021))
The drug is marketed under the brand name Aggrastat in the US by Medicure Pharma, in China by Eddingpharm, and in the rest of the world by Correvio International Sàrl.

According to the US Orange Book, it was first approved in the US on 20 April 2000.  Patent numbers 5733919; 5965581 and 5972967 all expired in October 2016. Patent 5978698 expired in October 2017. Patent 6136794 expired in January 2019. Patent 6770660 expires in June 2023.

== References ==
((Reflist))

== Further reading ==
* ((cite journal | vauthors = Hartman GD, Egbertson MS, Halczenko W, Laswell WL, Duggan ME, Smith RL, Naylor AM, Manno PD, Lynch RJ, Zhang G | title = Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors | journal = Journal of Medicinal Chemistry | volume = 35 | issue = 24 | pages = 4640–2 | date = November 1992 | pmid = 1469694 | doi = 10.1021/jm00102a020 ))

((Antithrombotics))
((Portal bar | Medicine))

[[Category:Glycoprotein IIb/IIIa inhibitors]]
[[Category:Sulfonamides]]
[[Category:4-Piperidinyl compounds]]
[[Category:Phenol ethers]]
[[Category:Butyl compounds]]

Pages transcluded onto the current version of this page (help):

Tirofiban (edit)
Template:Abbr (view source) (protected)
Template:Ambox (view source) (template editor protected)
Template:Antithrombotics (edit)
Template:Button (view source) (template editor protected)
Template:Cascite (view source) (template editor protected)
Template:Chem molar mass (view source) (template editor protected)
Template:Chem molar mass/format (view source) (template editor protected)
Template:Chembox Elements/molecular formula (view source) (template editor protected)
Template:Chemspidercite (view source) (template editor protected)
Template:Cite journal (view source) (protected)
Template:Cite web (view source) (protected)
Template:Collapsible list (view source) (template editor protected)
Template:Drugbankcite (view source) (template editor protected)
Template:Drugbox (view source) (template editor protected)
Template:Drugs.com (view source) (template editor protected)
Template:Ebicite (view source) (template editor protected)
Template:EditAtWikidata (view source) (protected)
Template:Endplainlist (view source) (protected)
Template:Engvar (view source) (template editor protected)
Template:Fdacite (view source) (template editor protected)
Template:Find sources mainspace (view source) (template editor protected)
Template:Flatlist (view source) (protected)
Template:Hlist/styles.css (view source) (protected)
Template:Infobox (view source) (template editor protected)
Template:Infobox drug (view source) (template editor protected)
Template:Infobox drug/chemical formula (view source) (template editor protected)
Template:Infobox drug/data page link (view source) (template editor protected)
Template:Infobox drug/formatATC (view source) (template editor protected)
Template:Infobox drug/formatCASnumber (view source) (template editor protected)
Template:Infobox drug/formatChEBI (view source) (template editor protected)
Template:Infobox drug/formatChEMBL (view source) (template editor protected)
Template:Infobox drug/formatChemDBNIAID (view source) (template editor protected)
Template:Infobox drug/formatChemSpider (view source) (template editor protected)
Template:Infobox drug/formatCompTox (view source) (template editor protected)
Template:Infobox drug/formatDrugBank (view source) (template editor protected)
Template:Infobox drug/formatIUPHARBPS (view source) (template editor protected)
Template:Infobox drug/formatJmol (view source) (template editor protected)
Template:Infobox drug/formatKEGG (view source) (template editor protected)
Template:Infobox drug/formatPDBligand (view source) (template editor protected)
Template:Infobox drug/formatPubChemCID (view source) (template editor protected)
Template:Infobox drug/formatPubChemSID (view source) (template editor protected)
Template:Infobox drug/formatUNII (view source) (template editor protected)
Template:Infobox drug/legal status (view source) (template editor protected)
Template:Infobox drug/licence (view source) (template editor protected)
Template:Infobox drug/maintenance categories (view source) (template editor protected)
Template:Infobox drug/non-ref-space (view source) (extended confirmed protected)
Template:Infobox drug/pregnancy category (view source) (template editor protected)
Template:Infobox drug/title (view source) (template editor protected)
Template:Keggcite (view source) (template editor protected)
Template:KillMarkers (view source) (extended confirmed protected)
Template:Main other (view source) (protected)
Template:More citations needed (view source) (template editor protected)
Template:Multiple issues (view source) (template editor protected)
Template:Multiple issues/styles.css (view source) (template editor protected)
Template:Navbox (view source) (template editor protected)
Template:Nobold (view source) (template editor protected)
Template:Nobold/styles.css (view source) (template editor protected)
Template:Nowrap (view source) (protected)
Template:Pagetype (view source) (protected)
Template:PharmNavFootnote (view source) (template editor protected)
Template:Plainlist (view source) (protected)
Template:Plainlist/styles.css (view source) (protected)
Template:Portal bar (view source) (template editor protected)
Template:Refimprove (view source) (template editor protected)
Template:Reflist (view source) (protected)
Template:Reflist/styles.css (view source) (protected)
Template:SDcat (view source) (protected)
Template:Short description (view source) (protected)
Template:Short description/lowercasecheck (view source) (protected)
Template:Stdinchicite (view source) (template editor protected)
Template:Str number/trim (view source) (protected)
Template:Technical (view source) (template editor protected)
Template:Template other (view source) (protected)
Template:Tick (view source) (template editor protected)
Template:Unbulleted list (view source) (template editor protected)
Template:Unreferenced (view source) (template editor protected)
Template:Unreferenced section (view source) (template editor protected)
Template:Val (view source) (template editor protected)
Template:Yesno (view source) (protected)
Module:Arguments (view source) (protected)
Module:Category handler (view source) (protected)
Module:Category handler/blacklist (view source) (protected)
Module:Category handler/config (view source) (protected)
Module:Category handler/data (view source) (protected)
Module:Category handler/shared (view source) (protected)
Module:Check for unknown parameters (view source) (protected)
Module:Citation/CS1 (view source) (protected)
Module:Citation/CS1/COinS (view source) (protected)
Module:Citation/CS1/Configuration (view source) (protected)
Module:Citation/CS1/Date validation (view source) (protected)
Module:Citation/CS1/Identifiers (view source) (protected)
Module:Citation/CS1/Utilities (view source) (protected)
Module:Citation/CS1/Whitelist (view source) (protected)
Module:Citation/CS1/styles.css (view source) (protected)
Module:Collapsible list (view source) (template editor protected)
Module:Convert (view source) (template editor protected)
Module:Convert/data (view source) (template editor protected)
Module:Convert/text (view source) (template editor protected)
Module:Disambiguation/templates (view source) (protected)
Module:EditAtWikidata (view source) (protected)
Module:Engvar (view source) (template editor protected)
Module:Find sources (view source) (template editor protected)
Module:Find sources/config (view source) (template editor protected)
Module:Find sources/links (view source) (template editor protected)
Module:Find sources/templates/Find sources mainspace (view source) (template editor protected)
Module:Gapnum (view source) (extended confirmed protected)
Module:Infobox (view source) (template editor protected)
Module:Infobox/styles.css (view source) (template editor protected)
Module:InfoboxImage (view source) (template editor protected)
Module:List (view source) (protected)
Module:Math (view source) (protected)
Module:Message box (view source) (protected)
Module:Message box/ambox.css (view source) (protected)
Module:Message box/configuration (view source) (protected)
Module:Namespace detect/config (view source) (protected)
Module:Namespace detect/data (view source) (protected)
Module:Navbar (view source) (protected)
Module:Navbar/configuration (view source) (protected)
Module:Navbar/styles.css (view source) (protected)
Module:Navbox (view source) (template editor protected)
Module:Navbox/configuration (view source) (template editor protected)
Module:Navbox/styles.css (view source) (template editor protected)
Module:Pagetype (view source) (protected)
Module:Pagetype/config (view source) (protected)
Module:Pagetype/disambiguation (view source) (protected)
Module:Pagetype/setindex (view source) (protected)
Module:Pagetype/softredirect (view source) (protected)
Module:ParameterCount (view source) (template editor protected)
Module:Portal (view source) (template editor protected)
Module:Portal/images/m (view source) (template editor protected)
Module:Portal bar (view source) (template editor protected)
Module:Portal bar/styles.css (view source) (template editor protected)
Module:SDcat (view source) (protected)
Module:String (view source) (protected)
Module:TableTools (view source) (protected)
Module:TemplatePar (view source) (template editor protected)
Module:Unstrip (view source) (template editor protected)
Module:Unsubst (view source) (protected)
Module:Val (view source) (template editor protected)
Module:Wikitext Parsing (view source) (protected)
Module:Yesno (view source) (protected)

Return to Tirofiban.

Retrieved from "https://en.wikipedia.org/wiki/Tirofiban"